Advertisement

Lung Cancer Screening Increases Percentage of Stage I Cases Detected, While Reducing Percentage of Stage IV Cases Detected


Advertisement
Get Permission

Implementing lung cancer screening at four diverse health-care systems resulted in an 8.4% increase in the number of stage I lung cancers detected and a 6.6% decrease in the detection of stage IV disease, according to research published by Vachani et al in the Journal of Thoracic Oncology.

The Population-based Research to Optimize the Screening Process (PROSPR) Lung Consortium is a collaboration of five diverse health-care systems, including Henry Ford Health System, Kaiser Permanente Colorado, Kaiser Permanente Hawaii, Marshfield Clinic Health System, and the University of Pennsylvania Health System. Marshfield Clinic Health System was not included in this study. According to lead investigator Anil Vachani, MD, of the University of Pennsylvania, despite the positive results from the NLST and NELSON trials, the effectiveness of lung cancer screening in clinical practice has not been clearly demonstrated. For example, Dr. Vachani pointed out that study procedures utilized in the NLST and NELSON trials resulted in very high adherence to annual screening, but observed rates in community settings have been considerably lower, including at the health systems included in this analysis.

Study Details

To examine this issue in greater detail, Dr. Vachani and colleagues from four other health-care systems performed a multicenter cohort study of patients diagnosed with a primary lung cancer between January 1, 2014, and September 30, 2019. The primary outcome variables were cancer stage distribution and annual age-adjusted lung cancer incidence. The primary exposure variable was receipt of at least one low-dose computed tomography scan for lung cancer screening prior to cancer diagnosis.

Dr. Vachani and colleagues restricted the cohort to adults diagnosed with primary in situ or invasive lung cancer between January 1, 2014, and September 30, 2019. Participants were excluded if they had a previous lung cancer diagnosis, were younger than age 55 or older than age 80, or had a tobacco use history documented as “never” or was missing.

Screening Results

Of the 3,678 individuals who were diagnosed with an incident lung cancer during the study period, 404 (11%) of these were diagnosed after the initiation of lung cancer screening. As screening volume increased, the proportion of patients diagnosed with lung cancer after screening initiation also rose—from 0% in Q1 of 2014 to 20% in Q3 of 2019. Lung cancer screening did not result in a significant change in the overall incidence of lung cancer (average annual percent change (AAPC) = –0.8, 95% confidence interval [CI] = –4.7 to 3.2) between 2014 and 2018. Stage-specific incidence rates increased for stage I cancer (AAPC = 8.0, 95% CI = 0.8–15.7) and declined for stage IV disease (AAPC = –6.0, 95% CI = –11.2 to –0.5).

The annual rate of stage I lung cancer increased by an average of 8.4% and was accompanied by an average decline of 6.6.% in stage IV disease. By 2018, these changes in incidence resulted in a higher rate of stage I compared to stage IV cancers. This migration to early-stage disease with no change in the overall incidence of lung cancer suggests that implementation of screening was achieving the desired effect of identifying early-stage lung cancers that were destined to progress to more advanced stages of disease, and without resulting in a significant rate of overdiagnosis.

“Implementation of lung cancer screening at four diverse health-care systems has resulted in a favorable shift to a higher incidence of stage I cancer with an associated decline in stage IV disease,” Dr. Vachani said. “Overall, lung cancer incidence did not increase, suggesting a limited impact of overdiagnosis.”

Disclosure: For full disclosures of the study authors, visit jto.org.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement



Advertisement